Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
GlobalData on MSN2d
Gilead and MSD to advance once-weekly HIV treatment to Phase IIIThe companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Laura M. Mann, PhD, MPH, from the US Centers for Disease Control and Prevention in Atlanta, and colleagues used the IQVIA Real-World Longitudinal Prescription Data database (2013 to 2023) to examine ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
With just 15 days until the presidential election, the federal government is proposing new rules that aim to bolster ...
Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...
An analysis by Li Tao, MD, MS, PhD, director of real-world evidence at Gilead Sciences, and colleagues looked at statistical ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Historically, as mentioned, PrEP has been used to treat cisgender gay men, especially in light of the HIV crisis of the 1980s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback